GlaxoSmithKline agreed to pay $20 million to settle Securities and Exchange Commission (SEC) charges of violating the Foreign Corrupt Practices Act (FCPA) when its China-based subsidiaries engaged in pay-to-prescribe schemes to increase sales. An SEC investigation found that the schemes took place between at least 2010 and June 2013 and involved the transfer of money, gifts, and other things of value to Chinese officials, which led to millions of dollars in increased sales of Glaxo products. The SEC found that Glaxo violated the FCPA’s internal controls and books-and-records provisions. Glaxo consented to the order without admitting or denying the findings.